Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Acute myeloid leukemia (AML) frequently progresses to refractory or relapsed disease, creating a critical need for new treatments.
• Standard therapies are lacking for patients with relapsed or refractory AML.
• Targeted small molecule inhibitors have shown success in other cancers, prompting investigation in AML.

Purpose of the Study:

• To review emerging small molecule inhibitors for acute myeloid leukemia.
• To highlight targeted agents and their mechanisms in preclinical and early clinical settings.

Main Methods:

• Literature review of preclinical studies.
• Analysis of early-phase human clinical trials.

Main Results:

• Identification of selective small molecule inhibitors targeting key proliferation and survival pathways in AML.
• Evaluation of therapeutic agents in preclinical models and initial human trials.

Conclusions:

• Small molecule inhibitors represent a promising therapeutic strategy for relapsed/refractory AML.
• Further research and clinical development are warranted for these novel agents.